All weight loss approaches, including laparoscopic adjustable gastric banding, are associated with coincident reductions in energy expenditure. This highlights the potential to exploit adjuvant pharmacotherapies to elevate energy expenditure or at least counteract its compensatory reduction and, in turn, enhance the efficacy of the adjustable gastric band (AGB). Diet–induced obese male Sprague Dawley rats were either sham-operated or fitted with an AGB just below the gastro-oesophageal junction, mimicking the situation in human surgeries. Rats in each of these groups were then divided into cohorts that received either vehicle or Contrave (bupropion 20 mg/kg/day + naltrexone 1 mg/kg/day) via twice–daily subcutaneous injections. A sub–effective dose (bupropion 5mg/kg/day + naltrexone 0.25mg/kg/day) was also tested to further elucidate the interaction and possible synergy between the combined treatment of Contrave and AGB inflation. Metabolic parameters, including food intake, body weight and fat mass were assessed. Biotelemetry devices implanted between the interscapular lobes of brown adipose tissue (BAT) were used to assess the impact of AGB on energy expenditure. Inflation of the AGB caused a reduction in body weight gain that was further enhanced by co-treatment with Contrave (p<0.05). The positive impact on weight loss induced commensurate reductions in fat mass (p<0.05) that are also associated with reductions in energy expenditure, which can be ameliorated by co–treatment with Contrave. These data support the notion that adjuvant therapies may improve AGB–induced satiety and weight loss, possibly via an action on energy expenditure. This may direct implications towards the clinical situation.